Cediranib (AZD2171), which targets VEGFR-1, -2 and -3, is now being tested in platinum-sensitive relapsed ovarian cancer in a three-arm randomised placebo-controlled phase III trial in combination with carboplatin–paclitaxel (ICON6). The gene discussed is FLT1; the disease is ovarian cancer.